Recombinant human erythropoietin (3SBio/Biolotus)
重组人促红素（3SBio/Biolotus）
Report date: 2023/12/29 09:39:52
Base Information
Drug NameRecombinant human erythropoietin (3SBio/Biolotus)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved Indications
Approved Indications in China
Original Approved Country/Territory
Original Approved Date1998/01/01
Country/Territory
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShenyang Sunshine Pharmaceutical Co LtdBiolotus
China Registration ClassN/A
Develop Information
Active CompaniesShenyang Sunshine Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC Code
Related LinksN/A